Related Links
ARALAST NP AATmosphere Program
Support for Alphas and families from the ARALAST NP AATmosphere program.
Associations
These links are provided for your convenience. However, they lead to external websites not created, managed, or maintained by Baxter. Baxter is not responsible for, and does not necessarily endorse, the opinions or products represented on these external pages.
Educational and Support Organizations for Alpha-1
Alpha-1 Association
1225 Eye Street NW, Suite 1225
Washington, DC 20005-5918
800-521-3025
www.alpha1.org
Alpha-1 Foundation
2937 SW 27th Avenue, Suite 302
Miami, FL 33133
1-877-2-CURE-A1
www.alphaone.org
Alpha-1 Advocacy Alliance
P.O. Box 202, 103 Rapidan Church Lane
Wolftown, VA 22748
1-866-FOR-A1AA or 1-866-367-2122
www.alpha1advocacy.org
Patient Services Incorporated
P.O. Box 1602
Midlothian, VA 23113
1-800-366-7741
www.uneedpsi.org
Pulmonary Education & Research Foundation
American Lung Association
Medical Professional Organizations
American Thoracic Society (ATS)
American College of Chest Physicians (CHEST)
American Academy of Allergy, Asthma & Immunology (AAAAI)
American Association for Respiratory Care (AARC)
Global Initiative for Chronic Obstructive Lung Disease
Journal for Respiratory Care Practitioners
Alphas Online
Bill Poplett
Online Education Resources
National Library of Medicine
National Heart, Lung, and Blood Institute
Genetics Home Reference (Service of the National Library of Medicine)
Everything Respiratory Magazine
ARALAST NP [Alpha1-Proteinase Inhibitor (Human)]
ARALAST NP is indicated for chronic augmentation therapy in patients having congenital deficiency of A1-PI with clinically evident emphysema. ARALAST NP is not indicated as therapy for lung disease patients in whom congenital A1-PI deficiency has not been established.
The effect of augmentation therapy with ARALAST NP on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been demonstrated in randomized, controlled clinical trials.
Please review the detailed Important Risk Information and the Full Prescribing Information
Please review the detailed Important Risk Information and the Full Prescribing Information
